CD274 and non-small cell lung carcinoma: Immunotherapies targeting PD1/PD-L1 have shown potential efficacy in a wide range of tumors, such as melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and Hodgkin’s lymphoma [16–19].